S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Millendo Therapeutics Stock Price, Forecast & Analysis (NASDAQ:MLND)

$7.57
-0.21 (-2.70 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$7.57
Now: $7.57
$7.98
50-Day Range
$6.59
MA: $7.25
$8.12
52-Week Range
$4.56
Now: $7.57
$17.34
Volume15,100 shs
Average Volume35,740 shs
Market Capitalization$101.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.7
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone734-845-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$5.66 per share

Profitability

Net Income$-27,190,000.00

Miscellaneous

Employees32
Market Cap$101.53 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.


Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics Inc (NASDAQ:MLND) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.07. View Millendo Therapeutics' Earnings History.

What price target have analysts set for MLND?

7 equities research analysts have issued 12-month price targets for Millendo Therapeutics' stock. Their forecasts range from $22.00 to $29.00. On average, they expect Millendo Therapeutics' stock price to reach $25.14 in the next twelve months. This suggests a possible upside of 232.1% from the stock's current price. View Analyst Price Targets for Millendo Therapeutics.

What is the consensus analysts' recommendation for Millendo Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Millendo Therapeutics.

Has Millendo Therapeutics been receiving favorable news coverage?

News stories about MLND stock have trended positive this week, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Millendo Therapeutics earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Millendo Therapeutics.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 225,400 shares, a decline of 12.8% from the September 30th total of 258,600 shares. Based on an average trading volume of 31,500 shares, the days-to-cover ratio is currently 7.2 days. Currently, 3.6% of the shares of the stock are sold short. View Millendo Therapeutics' Current Options Chain.

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the folowing people:
  • Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 45)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Mr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)
  • Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)
  • Dr. Pharis Mohideen, Chief Medical Officer (Age 54)

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $7.57.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $101.53 million and generates $290,000.00 in revenue each year. The company earns $-27,190,000.00 in net income (profit) each year or ($17.58) on an earnings per share basis. Millendo Therapeutics employs 32 workers across the globe.View Additional Information About Millendo Therapeutics.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is http://www.millendo.com/.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MA, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]


MarketBeat Community Rating for Millendo Therapeutics (NASDAQ MLND)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote "Outperform" if you believe MLND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel